No Data
No Data
Compass Therapeutics to Participate in Upcoming Investor Events
Express News | Compass Therapeutics Inc. Files for Mixed Shelf of up to $300 Mln - SEC Filing
Institutional Investors Own a Significant Stake of 50% in Compass Therapeutics, Inc. (NASDAQ:CMPX)
Leerink Partners Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $5
Compass Therapeutics Strategy Pivot and Outperform Rating Amidst Clinical Setbacks
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $10
No Data
No Data